INDIANAPOLIS, Oct. 28, 2019 /PRNewswire/ -- Roche Diagnostics Corporation (RDC), part of the Roche Group (SIX: RO, ROG;OTCQX: RHHBY), today announced the appointment of Matthew Sause as President and Chief Executive Officer, North America, effective November 4, 2019. The position is based at RDC's North American headquarters in Indianapolis.
Sause joins Roche Diagnostics from Gilead Sciences, where he was Senior Vice President and Head of Global Commercial Product Strategy. Previously, Sause had a 17-year career with the Roche Group. In the Diagnostics division at Roche from 2002-14, Sause's experience included U.S.-based sales roles in Molecular Diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In the Pharmaceuticals division from 2014-19, Sause served as President of Country Operations in Peru and Korea before becoming Vice President and Lifecycle Leader for Roche's cancer medicine Tecentriq, a global role based at Genentech, member of the Roche Group, in South San Francisco. Sause succeeds Jack Phillips, who left Roche Diagnostics at the end of August.
"We are very pleased to have gained a highly experienced leader in Matt," said Thomas Schinecker, Chief Executive Officer of the Diagnostics division for the Roche Group. "He brings deep understanding of diagnostics in unique combination with many years of commercial leadership in pharmaceuticals. As we help our customers integrate the full range of diagnostics into the broader delivery of healthcare, Matt's experience will be invaluable."
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognized as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Gary Geipel, Corporate Communications
firstname.lastname@example.org or (317) 437-0439
SOURCE Roche Diagnostics